PUBLISHER: Grand View Research | PRODUCT CODE: 1869678
PUBLISHER: Grand View Research | PRODUCT CODE: 1869678
The global embolotherapy market size was estimated at USD 3.16 billion in 2024 and is projected to reach USD 5.82 billion by 2033, growing at a CAGR of 6.99% from 2025 to 2033. The market is primarily driven by the rising prevalence of cancer, vascular disorders, and trauma cases, which fuel demand for minimally invasive treatment options.
Technological advancements in embolic agents, such as drug-eluting beads, liquid embolic, and bioresorbable microspheres, along with innovative delivery devices like microcatheters and flow diverters, have improved procedural precision, safety, and clinical outcomes.
Moreover, increasing patient preference for less invasive procedures with shorter recovery times, expanding healthcare infrastructure in emerging markets, and supportive regulatory frameworks further accelerate adoption. Together, these factors create sustained growth opportunities and reinforce the market's upward trajectory.
The global rise in cancer treatments, trauma cases, and vascular disorders has amplified the need for advanced embolotherapy solutions. Hospitals, clinics, and interventional radiology centers are witnessing growing procedure volumes, creating continuous demand for effective embolic agents and delivery systems. This trend places additional pressure on healthcare facilities to adopt innovative, minimally invasive techniques that improve patient outcomes while maintaining safety and efficiency. To meet these needs, providers are increasingly turning to next-generation embolotherapy technologies that enable faster procedures, greater precision, and reduced complications.
For instance, in June 2025, Penumbra, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared and launched the Ruby XL System, the longest, largest, and softest coil available on the market. The Ruby XL System is designed to enable physicians to perform more efficient embolizations, potentially decreasing radiation exposure and improving outcomes-particularly in procedures involving large vessels and high-flow embolizations.
The rising prevalence of cancer and vascular diseases is a major driver of the embolotherapy industry because these conditions often require targeted, minimally invasive treatments to control bleeding, reduce tumor size, or manage abnormal blood vessels. Patients with liver cancer frequently undergo transarterial embolization to block the blood supply to tumors, slowing their growth while preserving surrounding healthy tissue. Arteriovenous malformations or gastrointestinal bleeding cases are increasingly managed with embolotherapy, as it provides an effective alternative to open surgery with shorter recovery times and fewer complications. According to WHO, the estimated number of new cases of liver and intrahepatic bile duct cancers among both sexes (ages 0-85+) is projected to increase from 2022 to 2040, as shown in the data frame and illustrated in the graph below.
Global Embolotherapy Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global embolotherapy market report based on the product, application, end use, and region: